IMIQUIMOD

Imiquimod is an immune-response modifier that stimulates interferon production to treat skin lesions such as warts and superficial cancers. Side effects include redness, swelling, irritation, and flu-like symptoms.

Product Description


Mechanism of Action

IMIQUIMOD (ID 26415) exhibits a multi-dimensional biochemical activity profile that affects cellular regulation at enzyme, receptor, and transcriptional levels. Its molecular interactions can alter phosphorylation cycles, modulate ionic homeostasis, influence mitochondrial respiration, and adjust redox-signaling pathways. Structural properties suggest specific affinity for regulatory proteins, enabling modulation of metabolic flux and cellular response thresholds.

Benefits and Advantages

This compound is suited for high-resolution mechanistic research, multi‑omics integration studies, receptor-binding experiments, enzyme-pathway mapping, and advanced pharmacodynamic modelling. It supports ROS-regulation assays, signalling-cascade analysis, cytoskeletal‑dynamics research, and metabolic adaptation models. Due to predictable biochemical behaviour, it is often used as a comparative reference in pathway‑perturbation studies.

  • Useful in mechanistic pharmacology and biochemical modelling
  • Applicable in oxidative-stress, mitochondrial-function and signalling studies
  • Reliable for transcriptional and proteomic profiling
  • Supports SAR (structure–activity relationship) investigations

Side Effects and Risks

Potential risks include mitochondrial overload, ROS imbalance, inadvertent receptor cross‑talk, disruption of ion-channel dynamics, and dose-dependent cytotoxicity. High exposure may trigger apoptosis, autophagy, or cellular stress-response activation. Controlled handling conditions and biosafety protocols are required for laboratory use.

Datasheet


Molecular Formula

C14H16N4

Molecular Weight

240.30 g/mol

CAS Number

99011-02-6

Storage Condition

Imiquimod topical cream should be stored at 4-25 °C; freezing should be avoided.

Solubility

Poorly soluble

Purity

Purity information is available upon request (COA).

Synonym

IMIQUIMOD; 99011-02-6; Aldara; Zyclara; 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine

IUPAC/Chemical Name

1-(2-methylpropyl)imidazo[4,5-c]quinolin-4-amine

InChl Key

DOUYETYNHWVLEO-UHFFFAOYSA-N

InChl Code

InChI=1S/C14H16N4/c1-9(2)7-18-8-16-12-13(18)10-5-3-4-6-11(10)17-14(12)15/h3-6,8-9H,7H2,1-2H3,(H2,15,17)

References

https://pubchem.ncbi.nlm.nih.gov/compound/57469;

3D Conformer.

(Click, turn or enlarge)

Download our GMP API Product List.

MedicaPharma is an EU-based supplier of GMP-certified APIs that serves leading healthcare institutions and research organizations.
Click here to download our full API product list.

Download